Business Context and Reporting Period
This Form 8-K Current Report was filed by InMed Pharmaceuticals Inc. on April 21, 2026 (with a signature date of April 27, 2026). The filing discloses the entry into material definitive agreements to amend existing Preferred Investment Options with Sabby Volatility Warrant Master Fund, Ltd. ("Sabby") and affiliates of H.C. Wainwright & Co., LLC ("Wainwright").
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of specific investment option amendments.
Material Changes Versus Prior Period
The primary material change involves a significant reduction in the exercise prices for existing Preferred Investment Options:
- Sabby Volatility Warrant Master Fund, Ltd.: The exercise price for up to 2,151,478 common shares was amended from $2.436 per share to $0.80 per share.
- H.C. Wainwright & Co., LLC Affiliates: The exercise prices for up to 153,236 common shares (on a post-consolidation basis) were amended from varying rates of $82.50, $20.75, and $3.2013 per share to a uniform $0.80 per share.
Guidance, Outlook, and Risks
The filing references a press release issued on April 27, 2026, which contains forward-looking statements. The document notes that actual results may differ materially from these statements due to various factors, though specific risks are not detailed in this summary text. The amendments represent a material modification to the rights of security holders.
Investor Verification Checklist
- Verify the full text of the Sabby Preferred Investment Option Amending Agreement (Exhibit 10.1) for conditions or restrictions on the new $0.80 exercise price.
- Review the Wainwright Preferred Investment Option Amending Agreements (Exhibit 10.2) to confirm the specific share allocations for each affiliate.
- Assess the potential for shareholder dilution resulting from the substantial reduction in exercise prices for over 2.3 million shares.
- Examine the Press Release (Exhibit 99.1) for management's rationale regarding the price adjustments and any updated strategic outlook.